This session focuses on developing equal access to transplant services for the Hispanic population, as well as on how equity-based approaches can be used as a model for treatment programs for other diseases, such as sickle cell disease, immunodeficiencies, cancer, and other chronic conditions.

Joins us as Dr. Schubiner describes how to differentiate pain due to nociceptive drivers versus central mechanisms and discusses effective communication strategies to provide health care professionals (HCPs) with the skills to describe central and peripheral mechanisms of pain.

This activity discusses the key takeaways from pandemic successes and setbacks, including the utilization of predictive analysis of potential infectious disease outbreaks, emergency preparedness, preventive health care programs and our expanded knowledge about vaccine development.

Bladder cancer (BC) is the tenth most common cancer worldwide, and its associated five-year survival rate declines rapidly (from 96% to 6%) as it progresses from in situ through local invasion, regional spread and finally to distal spread. Thus, early detection and timely therapeutic interventions are crucial to improve outcomes and reduce the burden of disease. Outcomes have been further improved by the integration of recently approved therapies for BC, the utilization of biomarkers to guide treatment plans and the opportunity for eligible patients with BC to enroll in clinical trials. For all treatment plans, effective communication among the health care team is crucial for providing comprehensive care for this condition. This activity will provide participants with an overview of early BC diagnosis and its impact on survival rates. It will explore recently approved therapies for BC both as standalone treatments and in combination with established therapeutic approaches. Emerging therapies and their potential benefits will be examined, and the value of biomarkers will be discussed. Participants will gain insight into treatment strategies to optimize patient outcomes in BC.